Immunol. (2005) 175:1483–90. doi:10.4049/jimmunol.175.3.1483 111. Walker C, Kristensen F, Bettens F, deWeck AL. Lymphokine regu lation of activated (G1) lymphocytes. I. Prostaglandin E2-induced inhi bition of interleukin2production. JImmunol. (1983)130:1770–3. 112. Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, et al. Checkpoint blockade cancer immunotherapy targets tumour-spec iﬁc mutantantigens. Nature.(2014)515:577–81.doi:10.1038/nature13988 Frontiers in Immunology | www.frontiersin.org 16 August 2019 | Volume 10 | Article 1832 Bassani-Sternberg et al. Personalized Vaccine for Pancreatic Cancer 113. Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bu mbaca S, et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature.(2014) 515:572–6.